A Genotype-Phenotype Urothelial Cancer Study
[Protocol 09-025] |
Bajorin, Dean, MD |
A Multicenter Study of Sonablate 500 HIFU Treatment for Locally Recurrent Prostate Cancer: the STAR Trial
[Protocol 09-164] |
Eastham, James, MD |
A Phase I Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer
[Protocol 09-035] |
Zelefsky, Michael, MD |
A Phase I Dose-Escalation Study of Image-Guided Radiation Therapy for Bladder Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy
[Protocol 10-031] |
Kollmeier, Marisa, MD |
A Phase I Study of AGS-16C3F in Patients with Clear Cell or Papillary Renal Cell Cancer
[Protocol 12-162] |
Molina, Ana Maria, MD |
A Phase I Study of ASG-5ME Therapy Patients with Advanced Prostate Cancer
[Protocol 10-138] |
Morris, Michael, MD |
A Phase I Study of AT13387 Alone or with Abiraterone to Treat Castration-Resistant Prostate Cancer that Continues Growing Despite Abiraterone
[Protocol 12-248] |
Slovin, Susan, MD, PhD |
A Phase I Study of Axitinib plus Dalantercept for Patients with Metastatic Kidney Cancer
[Protocol 12-255] |
Voss, Martin, MD |
A Phase I Study of BMS-936558 in Combination with Sunitinib or Pazopanib in Patients with Metastatic Renal Cell Carcinoma
[Protocol 12-147] |
Voss, Martin, MD |
A Phase I Study of BMS-986015 plus BMS-936558 in Patients with Advanced Solid Tumors
[Protocol 12-224] |
Segal, Neil, MD, PhD |
A Phase I Study of DSTP3086S in Patients with Metastatic Castration-Resistant Prostate Cancer
[Protocol 11-016] |
Danila, Daniel, MD |
A Phase I Study of Yttrium-90 Attached to Chimeric Monoclonal Antibody CG250 in Patients with Advanced Renal Cancer
[Protocol 05-031] |
Larson, Steven, MD |
A Phase I Trial of Gemcitabine and Split-Dose Cisplatin plus Everolimus in Patients with Advanced Urothelial Cancer
[Protocol 10-106] |
Bajorin, Dean, MD |
A Phase I/II Study of Everolimus and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Non-Muscle-Invasive Bladder Cancer
[Protocol 10-165] |
Dalbagni, Guido, MD |
A Phase I/II Study of Ipilimumab Given with Abiraterone and Prednisone in Men with Metastatic Castration-Resistant Prostate Cancer
[Protocol 12-120] |
Danila, Daniel, MD |
A Phase I/IIa Study of Alpharadin® Plus Docetaxel in Patients with Bone Metastases from Castration-Resistant Prostate Cancer
[Protocol 10-086] |
Morris, Michael, MD |
A Phase IA/B Study of CC-115 in Castration-Resistant Prostate Cancer
[Protocol 12-080] |
Rathkopf, Dana, MD |
A Phase IB Study of SGN-75 plus Everolimus in Patients with CD70-Positive Metastatic Renal Cell Cancer
[Protocol 12-263] |
Molina, Ana Maria, MD |
A Phase IB/II study of E7080 plus Everolimus in Patients with Unresectable Advanced/Metastatic Renal Cell Carcinoma
[Protocol 10-084] |
Molina, Ana Maria, MD |
A Phase II Study Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Low-Risk Prostate Cancer
[Protocol 11-056] |
Zelefsky, Michael, MD |
A Phase II Study of Abiraterone, Prednisone, and Degarelix in Men with Recurrent Prostate Cancer and a Rising PSA
[Protocol 12-187] |
Scher, Howard, MD |
A Phase II Study of BKM120 in Metastatic Transitional Cell Carcinoma of the Urothelium
[Protocol 11-060] |
Bajorin, Dean, MD |
A Phase II Study of DN24-02 as Adjuvant Therapy in Patients with High-Risk HER2-positive Urothelial Cancers
[Protocol 11-163] |
Bajorin, Dean, MD |
A Phase II Study of Everolimus as Second-Line Therapy in the Treatment of Metastatic Renal Cell Carcinoma
[Protocol 11-197] |
Motzer, Robert, MD |
A Phase II Study of Gemcitabine and Cisplatin before Surgery in Patients with High-Grade Upper Tract Urothelial Carcinoma
[Protocol 10-208] |
Coleman, Jonathan, MD |
A Phase II Study of Gemcitabine and Pazopanib in Previously Untreated Patients with Advanced Urothelial Cancers Who Cannot Receive Cisplatin
[Protocol 11-191] |
Bajorin, Dean, MD |
A Phase II Study of MLN8237 in Patients with Advanced Prostate Cancer
[Protocol 13-042] |
Danila, Daniel, MD |
A Phase II Study of Neoadjuvant Dose-Dense Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer
[Protocol 12-071] |
Bajorin, Dean, MD |
A Phase II Study of New Treatment Approaches for High-Risk Renal Tumors
[Protocol 12-026] |
Kobos, Rachel, MD |
A Phase II Study of Response-Based Radiation Therapy for Patients with Localized Germ Cell Tumors of the Central Nervous System
[Protocol 12-243] |
Dunkel, Ira, MD |
A Phase II Study of Sorafenib in Children and Young Adults with Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, or Papillary Thyroid Cancer
[Protocol 12-139] |
Trippett, Tanya, MD |
A Phase II Trial of Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Cancer
[Protocol 10-226] |
Molina, Ana Maria, MD |
A Phase II Trial of Paclitaxel, Ifosfamide, and Cisplatin in Patients with Previously Untreated Advanced Germ Cell Tumors
[Protocol 07-044] |
Feldman, Darren, MD |
A Phase III Study Comparing Standard versus Extended Pelvic Lymph Node Removal During Bladder Cancer Surgery
[Protocol 12-049] |
Bochner, Bernard, MD |
A Phase III Study of BMS-936558 Versus Everolimus in Patients with Advanced or Metastatic Renal Cell Carcinoma Who Received Prior Anti-Angiogenic Therapy
[Protocol 12-159] |
Motzer, Robert, MD |
A Phase III Study of Cabozantinib (XL184) versus Mitoxantrone/Prednisone in Men with Previously Treated Symptomatic Castration-Resistant Prostate Cancer
[Protocol 12-032] |
Scher, Howard, MD |
A Phase III Study of Cabozantinib versus Prednisone in Metastatic Castration-Resistant Prostate Cancer after Prior Treatment
[Protocol 12-274] |
Rathkopf, Dana, MD |
A Phase III Study of Gemcitabine and Cisplatin with and without Bevacizumab in Patients with Advanced Transitional Cell Carcinoma
[Protocol 12-119] |
Rosenberg, Jonathan, MD |
A Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
[Protocol 07-041] |
Eastham, James, MD |
A Phase III Study of Pazopanib as Adjuvant Therapy for Patients with Localized or Locally Advanced Renal Cell Carcinoma Following Nephrectomy
[Protocol 10-162] |
Motzer, Robert, MD |
A Phase III Study of ProstAtakTM as an Adjuvant to Up-front Radiation Therapy for Localized Prostate Cancer
[Protocol 11-172] |
Zelefsky, Michael, MD |
A Phase III Trial of Short-Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed-Only Radiotherapy in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy
[Protocol 09-102] |
Zelefsky, Michael, MD |
A Pilot Study of a Geriatric-Specific Psychoeducational Intervention for Elderly Cancer Patients
[Protocol 09-116] |
Roth, Andrew, MD |
A Prospective Phase II Study of Brachytherapy in Men with Prostate Cancer that Returned after Prior External Beam Radiation Therapy
[Protocol 12-098] |
Kollmeier, Marisa, MD |
A Prospective Study of Quality of Life in Patients Undergoing Pelvic Exenteration
[Protocol 05-001] |
Chi, Dennis, MD |
A Prospective Study of Quality of Life in Patients with Invasive Bladder Cancer
[Protocol 08-076] |
Bochner, Bernard, MD |
A Randomized Trial of Pharmacological Penile Rehabilitation in the Preservation of
Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy
[Protocol 09-005] |
Mulhall, John, MD |
A Study of Degarelix Before Prostatectomy in Patients with Intermediate- to High-Risk Prostate Cancer
[Protocol 11-182] |
Rathkopf, Dana, MD |
Adoptive Transfer of Autologous T Cells Targeted to Prostate-Specific Membrane Antigen for the Treatment Of Castrate Metastatic Prostate Cancer
[Protocol 09-036] |
Slovin, Susan, MD, PhD |
Clinical Significance of Germline BRCA Mutations
[Protocol 96-051] |
Offit, Kenneth, MD |
